Browse By Topic: Avastin

Treating Macular Degeneration with Gene Therapy: New Research Shows Promise but Also Has Limitations

The Lancet logo Currently, there are a number of treatments for wet age-related macular degeneration, including the drugs Lucentis, Eylea, and Avastin, administered by injection with a very small needle directly into the eye after the surface has been numbed (also called

New Research: Emotional Support and Physician Communication Must Accompany Medical Treatment for Age-Related Macular Degeneration

Although the advent of anti-VEGF therapy (explained below), administered via eye injection with Lucentis, Eylea, or Avastin, has revolutionized the treatment (but not cure) of wet age-related macular degeneration (AMD), there remain a number of challenges associated with

Readers Beware: In a Dangerous and Unregulated Stem Cell Treatment, Patients Lose Sight After Stem Cells Are Injected Into Their Eyes

A retina with wet AMD Of all the eye research developments reported on the VisionAware blog, it is stem cell research for eye disease that generates the most inquiries from our readers. Many readers request information about stem cells, assuming that this is an established and widely-performed treatment for eye disease; others ask for help in finding a doctor who will administer "stem cell treatments." In response to these inquiries, my message is always the same: "Although stem cell research for eye disease has produced a small number of interesting results, it is in its very earliest safety-testing

New Research: Gene Editing as a Potential Treatment for Wet Macular Degeneration

At present, there are a number of current treatments for wet age-related macular degeneration, including the drugs Lucentis, Eylea, and Avastin, administered by injection with a very small needle directly into the eye after the surface has been numbed. There have also been a number of treatments that have proven to be inconclusive or unsuccessful after undergoing clinical trials, including

Clinical Trial Update: Squalamine Eye Drops for Wet Macular Degeneration

A retina with wet AMD Many readers have been following closely the development of Squalamine Eye Drops for wet age-related macular degeneration, hoping that a self-administered at-home eye drop could reduce, or even eliminate, the need for monthly or as-needed eye injections. Unfortunately, a clinical trial designed to test this concept has produced disappointing results: Squalamine Eye Drops failed to reduce the average number of

Clinical Trial Update: An Unsuccessful Trial of Combination Drugs Fovista and Lucentis for Macular Degeneration

A retina with wet AMD Although the advent of anti-VEGF therapy (explained below), administered via eye injection with Lucentis, Eylea, or Avastin, has revolutionized the treatment of wet age-related macular degeneration (AMD), there are still a

New Research Examines the Risk of Serious Eye Infection After Eye Injection Treatments for Macular Degeneration and Diabetic Eye Disease

Although the injectable drugs Lucentis, Eylea, or Avastin have revolutionized the treatment of wet macular degeneration and diabetic eye

New Macular Degeneration Research: Some Eyes not Responsive to Initial Eye Injection Treatments May Benefit from Continued Treatment without Switching Drugs

Although the advent of anti-VEGF therapy (also called eye injections, explained below) has revolutionized the treatment of wet age-related macular degeneration (AMD), there are still a number of persons – although in the minority – who do not respond to treatment. It is these "non-responders" or "reduced responders" who continue to pose significant challenges to doctors and researchers. Since there are not, at present, specific protocols that govern ophthalmologists' decisions to switch

The First Stem Cell Clinical Trial for Wet Macular Degeneration Is Underway in London

Please note: This is an older post and there have been setbacks and significant changes in stem cell research for eye disease since this was first published. For more current information, see Our Readers Want to Know: What Is the Progress of Stem Cell Research for Eye Disease? Answer: It Has a Very Long Way to Go. Also see the author's updates in the comment section below. A pioneering clinical trial of a new treatment derived from embryonic

A New Protein Shows Promise for the Treatment and Perhaps Even Prevention of Diabetic Eye Disease

Although there have been a number of significant advances in the treatment of diabetic eye disease, including Avastin, Lucentis, and Eylea injections, this approach has not proven to be effective in preventing the development of diabetic eye disease and proliferative diabetic retinopathy (explained below).

Avastin Injection Dosages Can Vary Significantly When Prepared by Compounding Pharmacies

A new study has investigated the safety, sterility, and dosage consistency of Avastin, a lower-cost intravenous cancer drug that is used "off label," via eye injection, to treat a range of retinal disorders including age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.

In Clinical Trials: A Potential Self-Administered Treatment for Diabetic Macular Edema

Aerpio Therapeutics, Inc. is a new Cincinnati, Ohio-based biopharmaceutical company focused on developing new therapies for vascular [i.e., blood vessel] diseases, including diabetic macular edema (DME) and age-related macular degeneration (AMD). This week, Aerpio announced positive clinical trial results for

Do Doctors Approach Macular Degeneration Differently When Treating Themselves?

Do retinal physicians approach wet age-related macular degeneration differently when treating themselves versus treating their patients? This question was explored in a recent presentation by Jonathan Prenner, M.D., at the 32nd Annual Meeting of the American Society of Retina Specialists in San Diego, California. The mission of the American Society of Retina Specialists is to provide a scientific forum for education, advance the understanding and treatment of retinal diseases, and

Is a "Treat and Extend" Injection Regimen More Beneficial for Wet Macular Degeneration?

The treatment of wet age-related macular degeneration (AMD) has – by all accounts – been revolutionized by the successful use of the injectable drugs Eylea, Lucentis, and Avastin. Yet, despite this treatment revolution, significant questions remain about the most effective dosing schedule for these medications: Is it monthly injections, a pro re nata [i.e., "as

New Research: Are Lucentis, Avastin, and Eylea Risk Factors for Increased Eye Pressure?

The injectable drugs Eylea, Lucentis, and Avastin have revolutionized the treatment of wet age-related macular degeneration (AMD). Nevertheless, questions continue to arise regarding the risks and complications that accompany this delivery system. At present, these drugs require monthly injections or a pro re nata [i.e.,

A Potential Intravenous Treatment for Wet Age-Related Macular Degeneration: Interleukin-18

A research group, composed of members from the Republic of Ireland, the United Kingdom, and the United States, has determined that a protein called interleukin-18 (IL-18), which is a component of the immune system linked to inflammatory disorders, has the ability to suppress production of the harmful bleeding/leaking blood vessels that characterize wet age-related macular degeneration (AMD). In addition, the researchers have demonstrated that IL-18 can be administered intravenously, which, if proven successful in human clinical trials, could offer advantages over the current treatment

A Potential Eye Drop Treatment for Wet and Dry Macular Degeneration

Researchers have identified a possible topical [i.e., eye drop] treatment for age-related macular degeneration (AMD) that is capable of inhibiting the characteristic symptoms of both the dry and wet forms of AMD. This "proof of concept" research is in its earliest stages and has been conducted only with laboratory mice. Nevertheless, the concept of a possible topical treatment shows promise for persons with AMD. The study, entitled Topical

Newest Therapies for Macular Degeneration are Reducing Vision Loss and Admissions to Long-Term Care

Here is some good news during National Age-Related Macular Degeneration Awareness Month. Two economists from Duke University have presented evidence that within the past ten years, since the introduction of anti-VEGF therapies (Lucentis, Avastin, and Eylea), older Americans with "wet" or exudative macular degeneration are less likely to experience

Eylea May Help When Patients Do not Respond to Lucentis or Avastin for Macular Degeneration

A new study, published "online first" on May 23, 2013 in the American Journal of Ophthalmology, concludes that Eylea therapy appears to be beneficial in a specific group of patients with wet age-related macular degeneration (AMD) whose symptoms are not responsive to either Lucentis or Avastin injections. The

In Europe, a New Radiation Therapy for Wet Macular Degeneration Reduces Need for Lucentis Injections

Oraya Therapeutics, Inc. has released the results of its INTREPID clinical trial evaluating the safety and effectiveness of Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD). The results indicate that a single dose of Oraya Therapy significantly reduces the need for Lucentis injections in persons with wet AMD, with

Which Real-Life Factors Influence Adherence to Lucentis Treatment for Macular Degeneration?

A recent study, published in Graefe's Archive for Clinical and Experimental Ophthalmology, has attempted to "identify factors and problems influencing treatment adherence in patients undergoing anti-VEGF therapy for neovascular age-related macular degeneration under real-life conditions." Graefe's Archive is an international journal that presents original clinical reports and experimental studies by ophthalmologists and vision research scientists in order to provide rapid

My Journey into Ophthalmology by Guest Blogger Irv Arons

Guest blogger Irv Arons is the creator of – and driving force behind – Irv Arons' Journal, an online compendium of the latest information on ophthalmics, medical lasers, and new drugs and devices for the treatment of age-related macular degeneration (AMD). Until his retirement in 2005, Irv was a consultant to the ophthalmic industry for over 30 years, and to the medical laser industry for over 20 years. I have been following Irv's informative blog for several years, and have great respect for his depth and breadth of knowledge regarding developments in stem cell therapy, gene therapy, and emerging

Using Microneedles To Deliver Drugs to the Retina: Helpful for Macular Degeneration?

Using a Microneedle for Drug Delivery to the Posterior Segment of the Eye was published in the July 2012 issue of Investigative Ophthalmology & Visual Science, the official journal of the Association for Research in Vision and Ophthalmology (ARVO). ARVO is an international organization that encourages and assists research, training, publication, and dissemination of knowledge in vision and ophthalmology, including low

Avastin and Lucentis for Macular Degeneration: Head-to-Head Once Again

Year Two results from the Comparison of Age-Related Macular Degeneration (AMD) Treatments Trials (CATT) that evaluated the effectiveness of Avastin (bevacizumab) versus Lucentis (ranibizumab) in a head-to-head clinical trial are now available. CATT is a multi-center, prospective clinical trial, funded by the National Eye Institute (NEI), a component agency

Avastin and Lucentis: Cardiovascular Risks? A New Canadian Study Says No

Last week, I read yet another intriguing research study regarding the age-related macular degeneration (AMD) drugs Lucentis and Avastin. The newly-released Canadian study investigated the risk of cardiovascular events [i.e., heart attack, congestive heart failure, blood clotting, and stroke] in patients who were receiving either Avastin or Lucentis injections for retinal disease. I've blogged about research results involving both drug treatments on a number of occasions, including

FDA Approves EYLEA™ for the Treatment of Wet Macular Degeneration

Anatomy of the EYLEA™ Drug Approval Process In February 2011, Regeneron Pharmaceuticals, Inc. announced that the company had submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for Regeneron's VEGF Trap-Eye (now called EYLEA™), a potential injectable drug treatment for wet age-related macular degeneration (AMD). The FDA next announced

A New Clinical Trial for Patients Who Do not Respond to Lucentis or Avastin for Macular Degeneration

This week, I learned about a new clinical trial for a drug that shows promise in the treatment of wet macular degeneration (AMD) in patients who have not responded to treatment with either Avastin or Lucentis, the two drug interventions most commonly used at present. The drug is called iSONEP™ and it has been created by Lpath, a San Diego, California-based pharmaceutical

Could Avastin and Lucentis Trigger Elevated Eye Pressure?

The August 2011 issue of the British Journal of Ophthalmology contains an article that caught my attention. In the article, entitled Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents (Translation: Sustained high pressure within the eye after injection with Avastin or Lucentis), the authors investigated several critical issues surrounding the longer-term safety of Lucentis and Avastin, injectable drugs used to treat macular degeneration. Some Background

Follow Us:

Blog Archive Browse Archive

Join Our Mission

Help us expand our resources for people with vision loss.